Nurix Therapeutics, Inc. (NRIX) Q3 FY2026 earnings

Reported results

• Total revenue for three months ended August 31, 2026 was $673.1 million, compared to $7.9 million for three months ended August 31, 2025, including $653.2 million in license revenue from Roche collaboration and $10.0 million in development milestone from Sanofi.
• Research and development expenses for three months ended August 31, 2026 were $79.3 million, compared to $86.1 million for three months ended August 31, 2025.
• General and administrative expenses for three months ended August 31, 2026 were $34.4 million, compared to $13.2 million for three months ended August 31, 2025.
• GAAP net income for three months ended August 31, 2026 was $549.8 million, or $4.73 per diluted share, compared to GAAP net loss of $86.4 million, or ($1.03) per diluted share, for three months ended August 31, 2025.
• Cash, cash equivalents and marketable securities were $1.1 billion as of August 31, 2026, compared to $592.9 million as of November 30, 2025.
• Enrolled first patient in Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg 600 mg once daily orally with pirtobrutinib in approximately 620 patients with relapsed/refractory CLL/SLL.

Guidance

• Company has runway into the second half of 2029 based on cash position of $1.1 billion as of August 31, 2026.
• Nurix remains eligible to receive approximately $455 million in future development, regulatory and commercial milestone payments associated with the Sanofi STAT6 program, in addition to potential royalties on future product sales.

Notes

The significant revenue increase is primarily attributable to the $700 million upfront payment from the Roche collaboration that closed during the quarter (of which $653.2 million was recognized as license revenue in Q3 2026). The company discontinued further clinical development of NX-2127 (zelebrudomide) as part of strategic prioritization of its wholly owned oncology portfolio.

Price and volatility reaction

The stock moved -0.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -41.4 vol points across the event (constant-maturity series — not the front-week crush).

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-13 (8-K, Item 2.02). Read the original filing on sec.gov.